Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.80 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.80 |
| ▸ | POLA1 | P09884 | 4/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | SOD1 | P00441 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | RXRB | P28702 | 1/20 | 0.64 |
| ▸ | RXRG | P48443 | 1/20 | 0.64 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podocaric Acid SCHEMBL160062 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL31181390 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL32474685 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL14389445 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL6312979 | 0.99 | NR1H2 (0.78) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL14696167 | 0.91 | SOD1 (0.77) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL15588775 | 0.91 | SOD1 (0.77) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL7024094 | 0.91 | SOD1 (0.77) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL2993726 | 0.89 | NR1H2 (0.76) | NR1H2NR1H3SOD1 | |
| SCHEMBL20561234 | 0.89 | NR1H2 (0.76) | NR1H2NR1H3SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049727-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| EP-4429644-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ModernaTX, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| EP-4192433-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | Modernatx, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023086465-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022032154-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-6908934-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049727-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | NR1H2 1628/4885NR1H3 1656/4885POLA1 1181/4885 |
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, APOB | NR1H2 1/4885NR1H3 2/4885POLA1 3183/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | NR1H2 1628/4885NR1H3 1656/4885POLA1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.